Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a clinical collaboration.

ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.

Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!

ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.